Interaction Color Code
Clinical Bottom Line
Minimal data to guide interaction: weigh risks and benefits of using this combination
Drug 1
Drug 1 dose
150 mg elvitegravir / 150 mg cobicistat once daily
Drug 1 effect
AUC increased 11%, Cmin increased 46%
Drug 2
Drug 2 dose
90 / 400 mg once daily
Drug 2 effect
Ledipasvir Cmax increased 65%, AUC increased 79%, Cmin increased 93%; Sofosbuvir Cmax increased 28%, AUC increased 47%; Sofosbuvir metabolite Cmax increased 29%, AUC increased 48%, Cmin increased 66%%
Clinical Effects
Potential increase in ledipasvir toxicity
Management
Manufacturer does not recommend co-administration of ledipasvir / sofosbuvir with Stribild due to interaction with tenofovir disoproxil fumarate. May coadminister with Genvoya.
Import ID
138
